Showing 3741-3750 of 4064 results for "".
- Peak Health Launches Plant-Based Regenerative Skincare Linehttps://practicaldermatology.com/news/peak-health-launches-plant-based-regenerative-skincare-line/2459940/Peak Health, launched Curere, a patented, regenerative skin care line created to treat a range of skin conditions, including acne, third-degree burns and necrosis. The line is made from all-natural ingredients to penetrate the dermal layer of skin and activate stem cells while also facili
- Rio Professor Develops Sunscreen for Hairhttps://practicaldermatology.com/news/rio-professor-develops-sunscreen-for-hair/2457538/A Rio professor and her team of students have developed the first national product capable of protecting hair from sun radiation. According to Ana Percebom, of the Scientific Technical Center of University PUC in Rio, none of the products currently sold have substances that actually block
- New Study Seeks to Improve Skin Cancer Prevention in Young Adults Via a New Websitehttps://practicaldermatology.com/news/new-study-seeks-to-improve-skin-cancer-prevention-in-young-adults-via-a-new-website/2457539/Researchers out of Rutgers Cancer Institute of New Jersey and colleagues from across the country are conducting a study to evaluate the reach and effectiveness of an online program targeted at skin cancer prevention in young adults. Investigators are refining an existing website to
- Almirall and X-Chem Team Up to Develop Oral Compounds for Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-and-x-chem-team-up-to-develop-oral-compounds-for-dermatological-diseases/2457545/Almirall, S.A. signed a collaborative research and license agreement with the X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases, a strategic area for Almirall. X-Chem, Inc. is a privately held biotechnology company focused on applying its indus
- Sinclair Pharma Announces Leadership Changeshttps://practicaldermatology.com/news/sinclair-pharma-announces-leadership-changes/2457491/Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclai
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- Ilumya Now Available for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-now-available-for-moderate-to-severe-plaque-psoriasis/2457534/Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for s
- Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanomahttps://practicaldermatology.com/news/opdivo-plus-yervoy-demonstrates-durable-four-year-survival-benefits-in-advanced-melanoma/2457552/Four-year data from the Phase 3 CheckMate-067 clinical trial—the longest follow-up to date—continue to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in
- Paradigm Shift: Cancer Patients Can Now Use Skin Creams During Radiation Therapyhttps://practicaldermatology.com/news/paradigm-shift-cancer-patients-can-now-use-skin-creams-during-radiation-therapy/2457556/Contrary to the advice most cancer patients receive when they go through radiation treatment, topical skin treatments, unless applied very heavily, do not increase the radiation dose to the skin and can be used in moderation before daily radiation treatments, according to a new study from the